Table 1.
The first and second line of therapy of HCC (Phase III trials).
| Drugs | Targets | Study | Primary Endpoint |
|---|---|---|---|
| Sorafenib | VEGFR, PDGFRβ, FLT3, RET | SHARP [45] | OS |
| Lenvatinib | VEGFR1-3, FGFR1-4, PDGFRα, RET, KIT | REFLECT [56] | OS |
| Atezolizumab/ Bevacizumab |
PDL-1 antibody/VEGF antibody | IMbrave150 [61] | OS |
| Regorafenib | VEGFR 1–3, tyrosine receptor protein kinase Tie, RET, PDGFR, FGFR, RAF | RESORCE [70] | OS |
| Cabozantinib | VEGFR2, c-Met, Kit, Axl, FLT3 | CELESTIAL [74] | OS |
| Ramucirumab | VEGFR-2 | REACH [76] | OS |
VEGFR, vascular endothelial growth factor receptor; PDGFRβ, platelet-derived growth factor receptor beta; FLT3, fms-like tyrosine kinase-3; FGR, basic fibroblast growth factor receptor; OS, overall survival.